

26 June 2018

Company Announcements Platform Australian Securities Exchange Level 4 20 Bridge Street SYDNEY NSW 2000

By Electronic Lodgement

Dear Sir/Madam

NOTICE UNDER SECTION 708A(12C)(e) OF THE CORPORATIONS ACT 2001

This cleansing notice (**Cleansing Notice**) is given by Algae.Tec Limited (ACN 124 544 190) (**Company**) under section 708A(12C)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**) as amended by ASIC Corporations (Sale Offers: Securities Issued on Conversion of Convertible Notes) Instrument 2016/82 and pursuant to an instrument of relief granted by the Australian Securities and Investments Commission on 20 June 2018 (copy attached).

The Company hereby confirms that:

- (a) the convertible notes described below will be issued without disclosure to an investor under Part 6D.2 of the Corporations Act; and
- (b) this Cleansing Notice has been given in accordance with section 708A(12C)(e) of the Corporations Act.

The issue of this Cleansing Notice enables the fully paid ordinary shares in the capital of the Company (**Shares**) issued on the conversion of the convertible notes issued by the Company on the terms described below, to be on-sold to retail investors without further disclosure.

BACKGROUND

1.1 Convertible Securities Agreement

As announced on 8 June 2018, the Company has entered into an agreement in relation to a convertible note facility with MEF I, L.P. (Noteholder) with an aggregate subscription price of up to AU\$7,000,000 (Facility) dated 7 June 2018 (Execution Date) (Convertible Securities Agreement). Pursuant to the Convertible Securities Agreement, the Company can issue convertible notes with a face value (Face Value) of US\$1.10 each in up to four tranches (Convertible Notes).

The Company expects to issue the first tranche of 775,170 Convertible Notes with a Face Value of US\$1.10 each (approximately AU\$1.42 based on an agreed exchange rate) to the Noteholder within 2 business days of the date of this Cleansing Notice for a subscription price of AU\$1,000,000 (Tranche A, Tranche A Convertible Notes).

The Company may issue up to an additional three tranches of Convertible Notes with a Face Value of US\$1.10 each to raise up to an additional AU\$6,000,000 (with the final two tranches being at the election of the Company), comprising of:

- (a) a second tranche of Convertible Notes which will be issued 5 Business Days after the Company obtains Shareholder approval for the issue of all securities that may be issued under the Convertible Securities Agreement (including the issue of the Convertible Notes and the Shares to be issued on conversion of the Convertible Notes) (Shareholder Approval) for a subscription price of AU\$1,000,000, subject to the satisfaction of the conditions set out in Section 4(f) below (Tranche B);
- (b) a third tranche of Convertible Notes which may be issued at the election of the Company 75 days after the Execution Date for a subscription price of AU\$2,000,000, subject to the satisfaction of the conditions set out in Section 4(g) below (**Tranche C**); and
- (c) a fourth tranche of Convertible Notes which may be issued at the election of the Company 120 days after the Execution Date for a subscription price of AU\$3,000,000, subject to the satisfaction of the conditions set out in Section 4(h) below (**Tranche D**).

The number of Convertible Notes to be issued under each tranche will be equal to the actual subscription price paid in US\$ by the Noteholder at the relevant issue date under each relevant tranche rounded upwards to the nearest whole number.

The Tranche A Convertible Notes will be issued under the Company's placement capacity under ASX Listing Rule 7.1. The issue of the Convertible Notes under Tranche B, Tranche C and Tranche D is subject to the Shareholder Approval being obtained. The Company will convene a meeting of its Shareholders to be held within 75 days of the issue date of the Tranche A Convertible Notes to seek the Shareholder Approval.

The conversion price of the Convertible Notes to be issued under each tranche is the lesser of:

- (a) 80% of the lowest daily volume weighted average price of the Shares during the 5 trading days prior to the date the Investor provides the Company with a notice of conversion; and
- (b) AU\$0.035,

save that the conversion price cannot be less than a floor price of AU\$0.01. The amount to be converted into Shares at each conversion of Convertible Notes is the aggregate Face Value of the Convertible Notes to be converted, converted into AU\$ at the date of conversion.

The maturity date of the Convertible Notes (**Maturity Date**) is the date which is twelve months after the issue of the Tranche D Convertible Notes other than where the Company does not obtain the Shareholder Approval within the next 75 days, in which case the Maturity Date will be the date which is three months after the issue of the Tranche A Convertible Notes.

The Company must pay to the Noteholder a commitment fee equal to 5% of the total subscription price of all Convertible Notes which can be issued under the Convertible Securities Agreement, being a total of AU\$350,000 (Commitment Fee). The Commitment Fee can be paid at the election of the Company by the

issue of Shares to the Noteholder at a deemed issue price equal to the volume weighted average price of Shares over the five trading days prior to relevant purchase date. The Shares to be issued by the Company in satisfaction of the Commitment Fee for Tranche A of AU\$50,000 will be issued under the Company's placement capacity under ASX Listing Rule 7.1 at a deemed issue price of AU\$0.0245 each.

A summary of the rights, privileges and restrictions attaching to the Convertible Notes as well as the redemption and repayment terms is set out in Section 4 of this Cleansing Notice.

The Directors of the Company (**Directors**) consider that the Facility is in the best interests of Shareholders as it provides funding for the near-term expansion and development of the Company's respective algae and medicinal cannabis-based operations.

2. CONTENTS OF THIS CLEANSING NOTICE

This Cleansing Notice sets out the following:

- (a) in relation to the Convertible Notes:
 - (i) the effect of the issue on the Company;
 - (ii) a summary of the rights and liabilities attaching to the Convertible Notes; and
 - (iii) a summary of the rights and liabilities attaching to the Shares that will be issued on the conversion of the Convertible Notes; and
- (b) any information that:
 - (i) has been excluded from continuous disclosure notices in accordance with the ASX Listing Rules; and
 - (ii) is information that investors and their professional advisors would reasonably require for the purpose of making an informed assessment of:
 - (A) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and
 - (B) the rights and liabilities attaching to the Shares; and
 - (iii) other information relating to the Company's status as a disclosing entity.

3. THE EFFECT OF THE ISSUE ON THE COMPANY

3.1 Effect of the issue on the Company

The principal effect of the issue of the Convertible Notes on the Company will be to:

(a) increase the Company's cash reserves by up to AU\$7,000,000 (before costs associated with the Convertible Notes issue and assuming the

- maximum number of Convertible Notes is issued pursuant to the Convertible Securities Agreement) with AU\$1,000,000 to be received by the Company pursuant to the issue of the Tranche A Convertible Notes;
- (b) increase the number of unquoted Convertible Notes on issue from 4 to 5,426,190 (refer below for the relevant assumptions), assuming the full draw down under the Convertible Securities Agreement occurs, of which 775,170 Convertible Notes will be issued under Tranche A;
- (c) give rise to the Company having a liability for the aggregate amount of the Face Value of the Convertible Notes issued under the Convertible Securities Agreement; and
- (d) if the Convertible Notes are converted, either wholly or in part to Shares, or the Commitment Fee is satisfied, either wholly or in part by the issue of Shares, increase the number of Shares on issue as a consequence of the issue of Shares on such conversion or such satisfaction of the Commitment Fee.

3.2 Pro Forma Consolidated Statement of Financial Position As at 30 April 2018 taking into account the issue of the Convertible Notes

- (a) Set out in Annexure A is a pro forma consolidated Statement of Financial Position as at 30 April 2018 for the Company based on the unaudited 30 April 2018 management accounts adjusted to reflect the proposed Convertible Notes issue (for both the issue of the Tranche A Convertible Notes and for the issue of all Convertible Notes which can be issued under the Convertible Securities Agreement) and has been prepared on the basis of the accounting policies normally adopted by the Company.
- (b) The pro forma financial information is presented in an abbreviated form in so far as it does not include all of the disclosures required by Australian Accounting Standards applicable to annual financial statements. The pro forma financial information is not audited. The classification of the allocations between debt and equity for the Convertible Notes may change in the future.

3.3 Potential effect on capital structure

- (a) As at the date of this Cleansing Notice, the total number of issued Shares is 905,820,550.
- (b) The capital structure of the Company will be affected by both the conversion of Convertible Notes by the Noteholder and the satisfaction of the Commitment Fee by the issue of Shares which will each result in additional Shares being issued.
- (c) Subject to limits on the conversion under the Convertible Securities Agreement, the Convertible Notes can be:
 - (i) converted at any time after their issue and prior to the Maturity Date at the request of the Noteholder;
 - (ii) redeemed prior to the Maturity Date at the request of the Company or by the Noteholder upon the occurrence of certain events (see Sections 4(n) and (p) below for further details);

- (iii) redeemed periodically as required by the Convertible Securities Agreement (see Section 4(o) below for further details); or
- (iv) automatically redeemed on the Maturity Date.
- (d) If the maximum number of Convertible Notes is issued under the Convertible Securities Agreement and the Noteholder converts all of such Convertible Notes into Shares, then based on a conversion price of AU\$0.01 per new Share (being the floor price under the Convertible Securities Agreement) and an exchange rate of US\$1.00 to AU\$1.29 (being the agreed exchange rate for the issue of the Tranche A Convertible Notes) and further assuming 100% of the Commitment Fee is satisfied by the issue of Shares at a 5 trading day volume weighted average price of Shares of AU\$0.0245 (being the deemed issue price of the Shares to be issued in satisfaction of the Commitment Fee for Tranche A) (Assumptions), 784,285,714 new Shares would be issued. The actual effect on the share capital of the Company will depend on what percentage of the Convertible Notes are actually converted, the price at which the conversion occurs, the US\$:AU\$ exchange rate at the date of issue of the Convertible Notes and the date of conversion, the 5 trading day volume weighted average price of the Shares at the date of conversion (upon which the number of Shares to be issued in satisfaction of the Commitment Fee will be based) and the proportion of the Commitment Fee which is actually satisfied by the issue of Shares.

The effect on the issued share capital of the Company upon the conversion of the maximum number of Convertible Notes which can be issued under the Convertible Securities Agreement and the issue of the maximum number of Shares which can be issued in satisfaction of the Commitment Fee is set out in the table below based on the Assumptions. This does not account for any default interest payable under the Convertible Securities Agreement being converted into Shares.

Shares	Number
Shares issued on the date of this Cleansing Notice	905,820,550
Shares issued upon conversion of the Tranche A Convertible Notes	110,000,000
Shares issued upon conversion of the Convertible Notes which can be issued under Tranche B, Tranche C and Tranche D ¹	660,000,000
Shares issued upon satisfaction of the Commitment Fee for Tranche A	2,040,816
Shares issued upon satisfaction of the Commitment Fee for Tranche B, Tranche C and Tranche D	12,244,898
Total Shares on issue following conversion of all Convertible Notes and satisfaction of the Commitment Fee 2,3	1,690,106,264

Options	Number
---------	--------

Options on issue at the date of this Cleansing Notice ⁴	281,799,121
Options issued under the Convertible Securities Agreement	Nil
Total Options on issue following conversion of all Convertible Notes and satisfaction of the Commitment Fee ^{2,3}	281,799,121

Convertible Notes	Number
Convertible Notes on issue at the date of this Cleansing Notice ⁴	4
Convertible Notes to be issued under Tranche A	775,170
Convertible Notes to be issued under Tranche B, Tranche C and Tranche D	4,651,020
Total Convertible Notes on issue following issue of the maximum number of Convertible Notes under the Convertible Securities Agreement	5,426,194

Notes:

- The Noteholder cannot convert any Convertible Notes or receive Shares in satisfaction of the Commitment Fee which would result in the Noteholder's voting power exceeding 19.99%. Based on the Shares on issue at the date of this Cleansing Notice the maximum number of Shares the Noteholder can be issued under the Convertible Securities Agreement is 181,073,528 Shares.
- As announced on 12 February 2018, the Company has agreed, subject to the satisfaction of conditions precedent, to issue 25,000,000 Shares and 25,000,000 Options exercisable at AU\$0.15 each or before the date that is three years from the date of issue to NS Technologies Pty Ltd as consideration for the acquisition of a 19.9% shareholding in NS Technologies Pty Ltd, the entry into an oil supply agreement and the grant of a licence.
- As announced on 22 December 2017, the Company has agreed, subject to the satisfaction of conditions precedent, to issue up to such number of Shares which is equal to 19.9% of the issued share capital of the Company at the date of issue and an equal number of Options exercisable at AU\$0.075 each or before the date that is 31 December 2020 to Medical Cannabis Limited as consideration for the grant of a licence.
- Details of the exercise prices and expiry dates of the Options on issue and the face value, maturity date and conversion prices of the convertible notes on issue are set out in the Company's Appendix 3B lodged with ASX on 15 June 2018.

4. RIGHTS AND LIABILITIES ATTACHING TO THE CONVERTIBLE NOTES TO BE ISSUED UNDER THE CONVERTIBLE SECURITIES AGREEMENT

The following is a broad summary of the rights, privileges and restrictions attaching to the Convertible Notes. The summary is not exhaustive and does not constitute a definitive statement of the rights and liabilities of the Noteholder.

(a) **Term**

The Maturity Date of the Convertible Notes is the date which is twelve months after the issue of the Tranche D Convertible Notes other than where the Company does not obtain the Shareholder Approval within 75 days of the issue date of the Tranche A Convertible Notes, in which case the Maturity Date will be the date which is three months after the issue of the Tranche A Convertible Notes.

(b) Face Value

The number of Convertible Notes to be issued under each tranche of the Convertible Securities Agreement will be equal to the actual subscription price paid in US\$ by the Noteholder under each relevant tranche rounded upwards to the nearest whole number. Each Convertible Note will be issued with a Face Value of US\$1.10. At the date of this Cleansing Notice, the total face value of the maximum number of Convertible Notes which can be issued under the Convertible Securities Agreement (based on the Assumptions) is US\$5,968,992 or AU\$7,700,000 (assuming an exchange rate of US\$1.00 to AU\$1.29).

(c) Subscription Price

The maximum subscription price payable by the Noteholder is AU\$7,000,000 (**Purchase Price**) as set out in the table below.

Tranche	Subscription Price (AU\$)
Tranche A	\$1,000,000
Tranche B	\$1,000,000
Tranche C	\$2,000,000
Tranche D	\$3,000,000

(d) Issue of Convertible Notes

The Convertible Notes will be issued as follows:

- (i) Tranche A within 2 business days of the date of this Cleansing Notice;
- (ii) Tranche B 5 Business Days after the Company obtains the Shareholder Approval;
- (iii) Tranche C at the election of the Company, 75 days after the Execution Date; and
- (iv) Tranche D at the election of the Company, 120 days after the Execution Date.

(e) Noteholder's Right to Opt Out

If any of the following events occur, the Noteholder may give written notice to the Company that it is opting out of the issue of Convertible Notes under the Convertible Securities Agreement:

(i) the average daily dollar trading volume of the Shares over any period of 10 trading days is less than AU\$100,000;

- (ii) the daily volume weighted average price of the Shares is less than or equal to \$0.01 on any 5 trading days;
- (iii) an event occurs which has a material adverse effect on:
 - (A) the assets, liabilities, results of operations, condition, business or prospects of the Company;
 - (B) the ability of the Company to perform its obligations under the Convertible Securities Agreement;
 - (C) the validity or enforceability against the Company of any material provision of the Convertible Securities Agreement; or
 - (D) the likely price or value of any Shares to be issued to the Noteholder.

except something arising solely from an act or omission of the Noteholder;

- (iv) the Company is not able to lodge a cleansing statement or prospectus in respect of the issue of Convertible Notes or Shares;
- (v) an Event of Default occurs (as defined in Annexure B);
- (vi) the Company does not obtain the Shareholder Approval within 75 days of the issue date of the Tranche A Convertible Notes.

(f) Conditions Precedent – Issue of Tranche B Convertible Notes

The issue of the Tranche B Convertible Notes is subject to the satisfaction (or waiver) of a number of conditions precedent, including the Company obtaining the Shareholder Approval.

(g) Conditions Precedent – Issue of Tranche C Convertible Notes

The issue of the Tranche C Convertible Notes is subject to the satisfaction (or waiver) of a number of conditions precedent, including:

- (i) the Company giving written notice to the Noteholder requesting Tranche C to occur no later than 50 days after the Execution Date:
- (ii) the Company obtaining the Shareholder Approval;
- (iii) the Company either obtaining a waiver in respect of ASX Listing Rule 7.3.2 permitting the Company to issue the Tranche C Convertible Notes after the 3 month period commencing on the date the Shareholder Approval is obtained (ASX Waiver) or seeking an additional shareholder approval for the issue; and
- (iv) the Company completing the first sale of a new algae product or algae to a new market.

(h) Conditions Precedent – Issue of Tranche D Convertible Notes

The issue of the Tranche D Convertible Notes is subject to the satisfaction (or waiver) of a number of conditions precedent, including:

- (i) the Company giving written notice to the Noteholder requesting Tranche D to occur no later than 110 days after the Execution Date:
- (ii) the Company obtaining the Shareholder Approval;
- (iii) the Company either obtaining the ASX Waiver or seeking an additional shareholder approval for the issue of the Tranche D Convertible Notes; and
- (iv) the Company completing its first commercial sale of nutraceutical quality algae oil in excess of US\$50,000.

(i) Interest

No interest is payable on the Convertible Notes unless an Event of Default occurs, in which case interest is payable on the Convertible Notes at a rate of 10% per annum. Such interest shall accrue daily and shall be compounded monthly, from the date of the Event of Default until the Company remedies the Event of Default or discharges the amount outstanding in full.

(j) Commitment Fee

The Company must pay to the Noteholder a commitment fee equal to 5% of the total subscription price of all Convertible Notes which can be issued under the Convertible Securities Agreement (**Commitment Fee**). The Commitment Fee can be paid at the election of the Company by the issue of Shares to the Noteholder at a deemed issue price equal to the volume weighted average price of Shares over the five trading days prior to relevant purchase date. The Commitment Fee is payable even where an issue of Convertible Notes does not occur.

(k) Security

The Convertible Notes are secured by a general security agreement over all of the assets of the Company in favour of the Noteholder.

(I) Conversion

Subject to the conversion restrictions noted below, the Noteholder may provide the Company with written notice of its election to convert Convertible Notes into Shares at the conversion price (**Conversion Notice**), being the lesser of:

- (i) 80% of the lowest daily volume weighted average price of the Shares during the 5 trading days prior to the date the Investor provides the Company with a notice of conversion; and
- (ii) AU\$0.035 (Fixed Conversion Price),

(Variable Conversion Price), save that the conversion price cannot be less than a floor price of AU\$0.01 (Floor Price) (Conversion Price).

The number of Shares issued will be equal to the aggregate US\$ Face Value of the Convertible Notes converted into AU\$ and divided by the Conversion Price.

The Noteholder cannot convert any Convertible Notes or receive Shares in satisfaction of the Commitment Fee which would result in the Noteholder's voting power in the Company exceeding 19.99%.

(m) **Protective Provisions**

Upon the occurrence of certain events, including a Share consolidation, subdivision, pro-rata cancellation of the Company's issued share capital, payment of a dividend to shareholders or a distribution of Shares to existing shareholders (other than by way of rights offering or a bonus issue), the Fixed Conversion Price and the Floor Price will be reduced or, as the case may be, increased, in the same proportion as the issued capital of the Company is, consolidated, subdivided or cancelled.

If the Company, after the Execution Date:

- (i) issues or agrees to issue Shares to any person at a per Share price which is less than the Fixed Conversion Price;
- (ii) issues Options to any person with an exercise price which is less than the Fixed Conversion Price; or
- (iii) issues any debt, equity or equity-linked securities to any person which are convertible into, exchangeable or exercisable for, or include the right to receive Shares or other securities at a fixed price which is less than the Fixed Conversion Price,

(all of which prices will be a **Lesser Price**) then the Fixed Conversion Price will be reduced to the Lesser Price.

(n) **Early Redemption**

The Company may at any time prior to the Maturity Date redeem some or all of the outstanding Convertible Notes by giving notice to the Noteholder (**Early Redemption Notice**). The Company may not give an Early Redemption Notice more than once in any period of 45 days. On or before the date which is 5 Business Days after the date of the Early Redemption Notice, the Company must pay the Noteholder (in US\$) an amount equal to 110% of the aggregate Face Value of the Convertible Notes being redeemed (where such redemption occurs during the first 180 days after the relevant purchase date) or an amount equal to 115% of the aggregate Face Value of the Convertible Notes being redeemed (where such redemption occurs afterward) (the **Redemption Amount**).

(O) Periodic Redemption

On the date which is one year after the issue date of the Tranche A Convertible Notes and every 30th day thereafter (the **Repayment Date**), the Company must redeem the lesser of:

- (i) 200,000 Convertible Notes; and
- (ii) the number of outstanding Convertible Notes,

by paying the Noteholder the Redemption Amount of the aggregate face value of those Convertible Notes.

(p) Redemption at Election of Noteholder

The Noteholder may, by notice to the Company, require the Company to redeem the outstanding Convertible Notes by paying the Redemption Amount in respect of such Convertible Notes to the Noteholder if the Company lists on the Toronto Stock Exchange or raises aggregate funds after the Execution Date of \$8,000,000.

Further, the Noteholder may, by notice to the Company, require the Company to redeem the outstanding Convertible Notes by paying the Noteholder 115% of the aggregate Face Value of such Convertible Notes if the Company does not obtain the Shareholder Approval within 75 days of the issue date of the Tranche A Convertible Notes or the daily volume weighted average price of the Shares is less than AU\$0.01 on 5 consecutive trading days.

(q) Redemption on Maturity Date

Any Convertible Notes outstanding at the Maturity Date must be redeemed on the Maturity Date at 115% of their aggregate Face Value.

(r) Events of Default

The Events of Default are set out in Annexure B to this Cleansing Notice. If an Event of Default occurs and:

- (i) either:
 - (A) it is not capable of being remedied; or
 - (B) it is capable of being remedied but has not been remedied to the satisfaction of the Noteholder within ten Business Days of the Noteholder notifying the Company of its occurrence; or
 - (C) there have been two or more previous Events of Default; and
- (ii) the Event of Default has not been expressly waived by the Noteholder in writing;

(an **Unremedied Default**)

then the Face Value of all Convertible Notes will (unless converted) automatically increase by 10% and the Noteholder may:

- (A) declare, by notice to the Company, the Redemption Amount of the amount outstanding and all other amounts payable by the Company under the Convertible Securities Agreement to be immediately due and payable by the Company to the Noteholder; and/or
- (B) terminate the Convertible Securities Agreement, by notice to the Company; and/or
- (C) exercise any other right, power or remedy granted to it by the Convertible Securities Agreement and/or otherwise permitted to it by law.

(s) Parity Value

In the event the Company fails to pay the Noteholder when due an amount payable under the Convertible Securities Agreement in relation to a conversion of, redemption of or failure to issue Convertible Notes, the Noteholder may require the Company to pay the Noteholder such amount in US\$ which is determined in accordance with the following formula (Parity Value):

 $PV = P/CP \times MV$

Where:

PV = the Parity Value;

P = the amount of the payment required to be made under the Convertible Securities Agreement (which has not been paid);

CP = the Variable Conversion Price, determined as if the date upon which payment was required to be made was the relevant conversion notice date; and

MV = the highest average volume weighted average price of the Shares of any period of 5 consecutive trading days during the period commencing on the date which is 5 trading days prior to date on which payment was required to be made and ending on the day immediately prior to the date upon which payment of the Parity Value is made.

(†) Transferability

The Convertible Notes are transferable, subject to the transferee executing a deed of covenant in favour of the Company agreeing to be bound by the provisions of the Convertible Securities Agreement and compliance at all times to the Corporations Act and any applicable law.

5. RIGHTS AND LIABILITIES ATTACHING TO SHARES ISSUED ON CONVERSION OF THE CONVERTIBLE NOTES

The Shares issued to the Noteholder on the conversion of the Convertible Notes under the Convertible Securities Agreement will rank equally in all respects with all of the Company's existing Shares. The rights attaching to the Shares, including new Shares to be issued to the Noteholder on the conversion of the Convertible Notes, are set out in the Company's constitution, and, in certain circumstances, regulated by the Corporations Act, the ASX Listing Rules and the general law.

The Company intends to apply to ASX for quotation of the Shares issued on conversion of any Convertible Notes.

Full details of the rights and liabilities attaching to Shares are set out in the Company's constitution, a copy of which can be inspected free of charge, at the Company's registered office during normal business hours.

The following is a broad summary of the rights, privileges and restrictions attaching to all Shares. This summary is not exhaustive and does not constitute a definitive statement of the rights and liabilities of Shareholders.

(a) General meetings

Shareholders are entitled to be present in person, or by proxy, attorney or representative to attend and vote at general meetings of the Company.

Shareholders may requisition meetings in accordance with section 249D of the Corporations Act and the Company's constitution.

(b) Voting rights

Subject to any rights or restrictions for the time being attached to any class or classes of Shares, at general meetings of Shareholders or classes of Shareholders:

- (i) each Shareholder entitled to vote may vote in person or by proxy, attorney or representative;
- (ii) on a show of hands, every person present who is a Shareholder or a proxy, attorney or representative of a Shareholder has one vote; and
- (iii) on a poll, every person present who is a Shareholder or a proxy, attorney or representative of a Shareholder shall, in respect of each fully paid Share held by him, or in respect of which he is appointed a proxy, attorney or representative, have one vote for the Share, but in respect of partly paid Shares shall have such number of votes as bears the same proportion to the total of such Shares registered in the Shareholder's name as the amount paid (not credited) bears to the total amounts paid and payable (excluding amounts credited).

(c) **Dividend rights**

Subject to the rights of any preference Shareholders and to the rights of the holders of any Shares created or raised under any special arrangement as to dividend, the Directors may from time to time declare a dividend to be paid to the Shareholders entitled to the dividend which shall be payable on all Shares according to the proportion that the amount paid (not credited) is of the total amounts paid and payable (excluding amounts credited) in respect of such Shares.

The Directors may from time to time pay to the Shareholders any interim dividends as they may determine. No dividend shall carry interest as against the Company. The Directors may set aside out of the profits of the Company any amounts that they may determine as reserves, to be applied at the discretion of the Directors, for any purpose for which the profits of the Company may be properly applied.

(d) Winding-up

If the Company is wound up, the liquidator may, with the authority of a special resolution of the Company, divide among the Shareholders in kind the whole or any part of the property of the Company, and may for that purpose set such value as he considers fair upon any property to be so divided, and may determine how the division is to be carried out as between the Shareholders or different classes of Shareholders.

The liquidator may, with the authority of a special resolution of the Company, vest the whole or any part of any such property in trustees upon such trusts for the benefit of the contributories as the liquidator thinks fit, but so that no Shareholder is compelled to accept any Shares or other securities in respect of which there is any liability.

(e) Shareholder liability

As the Shares to be issued on the conversion of the Convertible Notes will be fully paid shares, they will not be subject to any calls for money by the Directors and will therefore not become liable for forfeiture.

(f) Transfer of Shares

Generally, Shares are freely transferable, subject to formal requirements, the registration of the transfer not resulting in a contravention of or failure to observe the provisions of a law of Australia and the transfer not being in breach of the Corporations Act or the ASX Listing Rules.

(g) Future increase in capital

The allotment and issue of any new Shares is under the control of the Directors. Subject to restrictions on the issue or grant of securities contained in the ASX Listing Rules, the Company's constitution and the Corporations Act (and without affecting any special right previously conferred on the holder of an existing share or class of shares), the Directors may issue securities as they shall, in their absolute discretion, determine.

(h) Variation of rights

Pursuant to section 246B of the Corporations Act, the Company may, with the sanction of a special resolution passed at a meeting of Shareholders vary or abrogate the rights attaching to Shares.

If at any time the share capital is divided into different classes of Shares, the rights attached to any class (unless otherwise provided by the terms of issue of the shares of that class), whether or not the Company is being wound up, may be varied or abrogated with the consent in writing of the holders of three-quarters of the issued shares of that class, or if authorised by a special resolution passed at a separate meeting of the holders of the shares of that class.

(i) Alteration of constitution

In accordance with the Corporations Act, the Company's constitution can only be amended by a special resolution passed by at least three quarters of Shareholders present and voting at the general meeting. In addition, at least 28 days written notice specifying the intention to propose the resolution as a special resolution must be given.

6. COMPLIANCE WITH DISCLOSURE OBLIGATIONS

The Company is a "disclosing entity" under the Corporations Act and, as such, is subject to regular reporting and disclosure obligations under both the Corporations Act and the ASX Listing Rules.

These obligations require the Company to notify ASX of information about specific events and matters as they arise. In particular, the Company is obliged to continuously disclose to the market immediately any information which a reasonable person would expect to have a material effect on the price or the value of the Shares.

The Company is also required to prepare and lodge with ASIC yearly and half-yearly financial statements accompanied by a directors' statement and report, and an audit report or review. Copies of documents lodged with ASIC in relation to the Company may be obtained from, or inspected at, an ASIC office.

The Company will provide a copy of each of the following documents, free of charge, to any person on request:

- (a) the annual financial report most recently lodged by the Company with ASIC, being the financial report of the Company for the year ended 30 June 2017;
- (b) any half-year financial report lodged by the Company with ASIC after the lodgement of the annual financial report referred to in paragraph (a) and before the lodgement of this Cleansing Notice with ASX; and
- (c) any continuous disclosure notices given by the Company to ASX after the lodgement of the annual financial report referred to in paragraph (a) and before the lodgement of this Cleansing Notice with ASX.

A list of the continuous disclosure notices given by the Company to ASX after lodgement of the annual financial report referred to in paragraph (a) above and before the lodgement of this Cleansing Notice with ASX is set out in the table below.

Date	Announcement
15/06/2018	Cleansing Notice and Appendix 3B
14/06/2018	Market Update
14/06/2018	AEB Canadian Roadshow
08/06/2018	Algae.Tec Secures Funding to Fast Track Developments
06/06/2018	Request for Trading Halt
06/06/2018	Trading Halt
29/05/2018	Response to ASX Appendix 4C Query
10/05/2018	Partnership with Canadian-based Radient Technologies Inc.
30/04/2018	Quarterly Activities Report and Appendix 4C
23/04/2018	Algae.Tec Aqua Feed Division Update
17/04/2018	Form 603 Notice of initial substantial holder
11/04/2018	Appendix 3B
19/03/2018	Results of Meeting
28/02/2018	Appendix 4D Half Year Report
21/02/2018	Appendix 3B
19/02/2018	AEB Signs Distribution Agreement with USA Market Leader
15/02/2018	Notice of Extraordinary General Meeting/Proxy Form

12/02/2018 AEB to Exclusively License Pharmaceutical Delivery Platform 07/02/2018 Director Appointment/Resignation 31/01/2018 Quarterly Activities Report and Appendix 4C 29/01/2018 Amended Appendix 3B 25/01/2018 3.10.5A Disclosure and Appendix 3B 25/01/2018 Reinstatement to Official Quotation 25/01/2018 Algae.Tec Funding and Operational Update 25/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Voluntary Suspension 15/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec		
31/01/2018 Quarterly Activities Report and Appendix 4C 29/01/2018 Amended Appendix 3B 25/01/2018 3.10.5A Disclosure and Appendix 3B 25/01/2018 Reinstatement to Official Quotation 25/01/2018 Algae.Tec Funding and Operational Update 25/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	12/02/2018	AEB to Exclusively License Pharmaceutical Delivery Platform
29/01/2018 Amended Appendix 3B 25/01/2018 3.10.5A Disclosure and Appendix 3B 25/01/2018 Reinstatement to Official Quotation 25/01/2018 Algae.Tec Funding and Operational Update 25/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 27/01/2018 Ceasing to be a substantial holder 29/01/2018 Change of Director's Interest Notice 29/01/2018 Change of Director's Interest Notice 29/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 27/12/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	07/02/2018	Director Appointment/Resignation
25/01/2018 3.10.5A Disclosure and Appendix 3B 25/01/2018 Reinstatement to Official Quotation 25/01/2018 Algae.Tec Funding and Operational Update 25/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 12/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	31/01/2018	Quarterly Activities Report and Appendix 4C
25/01/2018 Reinstatement to Official Quotation 25/01/2018 Algae.Tec Funding and Operational Update 25/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	29/01/2018	Amended Appendix 3B
25/01/2018 Algae.Tec Funding and Operational Update 25/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Altanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	25/01/2018	3.10.5A Disclosure and Appendix 3B
25/01/2018 Voluntary Suspension 24/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Algae.Tec Management Q&A Session 30/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	25/01/2018	Reinstatement to Official Quotation
24/01/2018 Voluntary Suspension 23/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 01/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	25/01/2018	Algae.Tec Funding and Operational Update
23/01/2018 Voluntary Suspension 22/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	25/01/2018	Voluntary Suspension
22/01/2018 Voluntary Suspension 16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 31/10/2017 Allanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	24/01/2018	Voluntary Suspension
16/01/2018 Voluntary Suspension 15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	23/01/2018	Voluntary Suspension
15/01/2018 Trading Halt 09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	22/01/2018	Voluntary Suspension
09/01/2018 Ceasing to be a substantial holder 09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	16/01/2018	Voluntary Suspension
09/01/2018 Updated Independent Equity Research Report Published 08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Irrading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	15/01/2018	Trading Halt
08/01/2018 Change of Director's Interest Notice 04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Trading Halt Request 20/11/2017 Trading Halt Request 20/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	09/01/2018	Ceasing to be a substantial holder
04/01/2018 Algae.Tec Strategy Confirmed by Federal Government 29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	09/01/2018	Updated Independent Equity Research Report Published
29/12/2017 Form 604 Notice of change of interests of substantial holder 22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	08/01/2018	Change of Director's Interest Notice
22/12/2017 MCL and AEB join to develop Cannabis veterinary medications 22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	04/01/2018	Algae.Tec Strategy Confirmed by Federal Government
22/12/2017 QBL: MCL&AEB join to develop Cannabis veterinary medications 12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	29/12/2017	Form 604 Notice of change of interests of substantial holder
12/12/2017 Algae.Tec Submits Australian License Application 07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	22/12/2017	MCL and AEB join to develop Cannabis veterinary medications
07/12/2017 Form 604 Notice of change of interests of substantial holder 01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	22/12/2017	QBL: MCL&AEB join to develop Cannabis veterinary medications
01/12/2017 Algae.Tec Management Q&A Session 30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	12/12/2017	Algae.Tec Submits Australian License Application
30/11/2017 Results of Meeting 28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	07/12/2017	Form 604 Notice of change of interests of substantial holder
28/11/2017 Appointment of Executive Chairman / Managing Director 22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	01/12/2017	Algae.Tec Management Q&A Session
22/11/2017 Algae.Tec to Invest in Medicinal Cannabis Partner 20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	30/11/2017	Results of Meeting
20/11/2017 Trading Halt Request 20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	28/11/2017	Appointment of Executive Chairman / Managing Director
20/11/2017 Trading Halt 09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	22/11/2017	Algae.Tec to Invest in Medicinal Cannabis Partner
09/11/2017 Atlanta Plant Upgrade 31/10/2017 Quarterly Activities Report and Appendix 4C	20/11/2017	Trading Halt Request
31/10/2017 Quarterly Activities Report and Appendix 4C	20/11/2017	Trading Halt
	09/11/2017	Atlanta Plant Upgrade
27/10/2017 Notice of Annual General Meeting/Proxy Form	31/10/2017	Quarterly Activities Report and Appendix 4C
	27/10/2017	Notice of Annual General Meeting/Proxy Form
20/10/2017 Form 604 Notice of change of interests of substantial holder	20/10/2017	Form 604 Notice of change of interests of substantial holder

19/10/2017	Appendix 3B
19/10/2017	Change of Director's Interest Notice
18/10/2017	Form 604 Notice of change of interests of substantial holder
12/10/2017	Algae.Tec completes oversubscribed shortfall placement
05/10/2017	Appendix 3B
29/09/2017	Annual Report to shareholders
29/09/2017	Corporate Governance Statement and Appendix 4G

7. INFORMATION EXCLUDED FROM CONTINUOUS DISCLOSURE NOTICES

As at the date of this Cleansing Notice, the Company advises that it has fully complied with its disclosure obligations under the ASX Listing Rules and the Corporations Act, and, in particular, there is no information which the Company has excluded from any of its continuous disclosure notices given in accordance with the ASX Listing Rules and the Corporations Act as at the date of this Cleansing Notice which it would be reasonable for investors and their professional advisors to require for the purpose of making an informed assessment of:

- (a) the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; and
- (b) the rights and liabilities attaching to the Convertible Notes under the Facility and the Shares.

For more information please contact the Company Secretary on +61 8 9380 6790.

Yours sincerely

PETER HATFULL
DIRECTOR
ALGAE.TEC LIMITED

ANNEXURE A - PRO-FORMA CONSOLIDATED STATEMENT OF FINANCIAL POSITION FOR THE COMPANY AS AT 30 APRIL 2018

Balance Sheet					
30/04/2018					
	Current Managemen t Accounts	Adjustment	\$1 Million Facility	Adjustment	\$7 Million Facility
ASSETS					
Current Assets					
Cash and cash equivalents	1,274,812	950,000	2,224,812	6,650,000	8,874,812
Trade and other receivables	3,454,838		3,454,838		3,454,838
Other current assets	218,910		218,910		218,910
Total Current Assets	4,948,560		5,898,560		12,548,560
Non Current Assets					
Property, plant and equipment	263,302		263,302		263,302
Intangible Assets	1,142,230		1,142,230		1,142,230
Deferred Tax Asset	658,047		658,047		658,047
Other non-current assets	347,500		347,500		347,500
Total Other Assets	2,411,079		2,411,079		2,411,079
TOTAL ASSETS	7,359,639		8,309,639		14,959,639
LIABILITIES					
Current Liabilities					
Trade and other payables	1,212,205		1,212,205		1,212,205
Provisions	251,910		251,910		251,910
Borrowings	3,528,164	1,100,000	4,628,164	7,700,000	12,328,164
Total Current Liabilities	4,992,279		6,092,279		13,792,279
Non Current Liabilities					
Derivative Liability	0		0	1	0
Borrowings	0		0		0
Total Other Liabilities	0		0		0
TOTAL LIABILITIES	4,992,279		6,092,279		13,792,279
NET ASSETS	2,367,361		2,217,361		1,167,361

EQUITY					
Issued Capital	33,191,266		33,191,266		33,191,266
Translation Reserve	-6,413		-6,413		-6,413
Share Option Reserve	305,957		305,957		305,957
Accumulated Losses	-31,123,449	-150,000	- 31,273,449	-1,050,000	-32,323,449
TOTAL EQUITY	2,367,361		2,217,361		1,167,361

ANNEXURE B - EVENTS OF DEFAULT

Defined terms in this annexure are as used in the Convertible Securities Agreement unless otherwise defined in this Cleansing Notice.

Each of the following constitutes an Event of Default under the Convertible Securities Agreement.

- (a) The Company fails to repay the Redemption Amount in respect of the Convertible Notes to the Noteholder in cash on the Maturity Date.
- (b) The Company fails to repay the Redemption Amount in respect of the number of Convertible Notes specified in an Early Redemption Notice on or before the day which is 5 Business Days after the date on which the Company gives the Early Redemption Notice.
- (c) The Company fails to repay the Redemption Amount in respect of the outstanding Convertible Notes on or before the day which is 5 Business Days after the date on which the Noteholder gives notice in the circumstances listed in Section 4(p) above.
- (d) The Company fails to repay the Redemption Amount of the aggregate Face Value of the Repayment Amount number of Convertible Notes to the Noteholder in cash on a Repayment Date.
- (e) The Company breaches or otherwise fails to comply in full with any of its material obligations under the Convertible Securities Agreement or a cleansing statement (**Transaction Document**) (and does not cure that breach or failure within 5 Business Days of notice of it by the Noteholder) or any event of default (however described) occurs under any Transaction Document.
- (f) Any of the materials provided by the Company in connection with any Transaction Document is inaccurate, false or misleading in any material respect (including by omission), as of the date on which it is made or delivered.
- (g) The Company or any of its subsidiaries (**Group Company**) is, admits that it is, is declared by a court of competent jurisdiction to be, or is deemed under any applicable Law to be, insolvent or unable to pay its debts as and when they become due.
- (h) A Group Company is served with a statutory demand (in accordance with Division 2 of Part 5.4 of the Corporations Act) or a foreign equivalent that is not set aside within 20 Business Days.
- (i) A controller within the meaning of section 9 of the Corporations Act, administrator or similar officer is appointed over all or any of the assets or undertaking of any Group Company or any formal step preliminary to such appointment is taken.
- (j) An application or order is made, a proceeding is commenced, a resolution is passed or proposed in a notice of meeting, or an application to a court or other steps are taken, for the winding up or dissolution of any Group Company, or for any Group Company to enter an arrangement, compromise or composition with, or assignment for the benefit of, any of its creditors.
- (k) A Group Company ceases, suspends, or indicates that it may cease or suspend, the conduct of all or a substantial part of its business; or disposes, or indicates that it may dispose, of a substantial part of its assets.

- (I) A Group Company takes action to reduce its capital or pass a resolution referred to in section 254N(1) of the Corporations Act.
- (m) Any Convertible Notes or Noteholder's Shares are not issued to the Noteholder within 3 Business Days of the Purchase Date or Conversion Notice Date (as relevant).
- (n) Any Noteholder's Shares are not quoted on ASX by the third Business Day immediately following the date of their issue.
- (o) The Company fails to comply with the ASX Listing Rules in any material respect.
- (p) A stop order, suspension of trading, cessation of quotation, or removal of the Company or the Shares from the ASX Official List is requested by the Company or requested or imposed by any Governmental Authority; except for a suspension of trading not exceeding five Trading Days in a rolling twelve month period or as agreed to by the Noteholder.
- (q) A Transaction Document or a Contemplated Transaction has become, or is claimed (other than in a vexatious or frivolous proceeding) by any person other than the Noteholder or any of its Affiliates to be, wholly or partly void, voidable or unenforceable.
- (r) Any third person commences any action, investigation or proceeding against any person or otherwise asserts any claim which seeks to restrain, challenge, limit, modify or delay the right of the Noteholder or the Company to enter into any Transaction Documents or to undertake any of the Contemplated Transactions (other than in a vexatious or frivolous proceeding).
- (s) A Security Interest over an asset of a Group Company is enforced.
- (t) Any present or future liabilities, including contingent liabilities, of any Group Company for an amount or amounts totalling more than AUD\$250,000 are not satisfied on time, or become prematurely payable.
- (u) A Group Company is in default in a material respect under a document or agreement (including a Governmental Authorisation) binding on it or its assets which relates to financial indebtedness or is otherwise material.
- (v) A Material Adverse Effect occurs (except something arising solely from an act or omission of the Noteholder).
- (w) The Company does not obtain a Shareholder approval to the extent required for the purposes of ASX Listing Rule 7.1 or 7.4 so that a Contemplated Transaction may proceed without breaching ASX Listing Rule 7.1.
- (x) Any event of default (however described) occurs under the GSA.
- (y) Any Group Company grants any Security Interest over any of its assets, or a Security Interest comes into existence over any assets of any Group Company, without the prior written consent of the Noteholder

Australian Securities and Investments Commission Corporations Act 2001 – Paragraph 741(1)(b) – Declaration

Enabling legislation

1. The Australian Securities and Investments Commission (ASIC) makes this instrument under paragraph 741(1)(b) of the *Corporations Act 2001* (Act).

Title

2. This instrument is ASIC Instrument 18-0544.

Commencement

3. This instrument commences on 20 June 2018.

Declaration

- 4. Chapter 6D of the Act applies to an offer for sale of Shares as if paragraph 708A(5)(b) of the Act was modified by deleting the words "5 days" and substituting the words "7 days".
- 5. Chapter 6D of the Act applies to an offer for sale of Shares as if paragraph 708A(12C)(c) of the Act (as notionally inserted by Legislative Instrument 2016/82) was further modified by deleting the words "5 days" and substituting the words "7 days".

Where this instrument applies

- 6. Paragraph 4 of this instrument applies to an offer for sale of Shares where:
 - (a) the Shares are issued between the date of this instrument and 31 October 2018 to the Investor in payment of the relevant Commitment Fee payable to the Investor;
 - (b) trading in the fully paid shares of the Company on ASX Limited ACN 008 624 691 (ASX) is not suspended at any time during the period between the date of this instrument and the date upon which the Shares are issued; and
 - (c) in relation to each relevant issue of Shares, the Company has given ASX a notice under paragraph 708A(5)(e) of the Act that complies with subsection 708A(6) of the Act.

- 7. Paragraph 5 of this instrument applies to an offer for sale of Shares where:
 - (a) the Shares were issued to the Investor by reason of the conversion of Convertible Notes issued to the Investor;
 - (b) trading in the fully paid shares of the Company on the ASX is not suspended at any time during the period between the date of this instrument and the date of issue of the relevant Convertible Notes; and
 - (c) in relation to each relevant issue of Convertible Notes, the Company has given ASX a notice under paragraph 708A(12C)(e) of the Act (as notionally inserted by Legislative Instrument 2016/82) which complies with subsection 708A(12D) of the Act (as notionally inserted by Legislative Instrument 2016/82).

Interpretation

8. In this instrument:

Company means Algae. Tec Limited ACN 124 544 190.

Commitment Fee means an amount payable by the Company in conjunction with the issue of Convertible Notes to the Investor by the Company under the Convertible Securities Agreement.

Convertible Note means the convertible notes issued to the Investor by the Company pursuant to the Convertible Securities Agreement on the following basis:

Convertible Notes	Date of Issue	Purchase Price	No of Convertible Notes	Face Value (per Convertible Note)	
First Purchase Tranche A	Between 20 June 2018 and 27 June 2018 (inclusive)	A\$1,000,000	US\$ cost of the Purchase	US\$1.10	
First Purchase Tranche B	Within 7 days after the Company obtains shareholder approval for the issue (presently projected to be 31 July 2018)	A\$1,000,000	Price		
Second Purchase	Between 22 August 2018 and 29 August 2018 (inclusive)	A\$2,000,000			
Third Purchase	Between 5 October 2018 and 12 October 2018 (inclusive)	A\$3,000,000			

Convertible Securities Agreement means the securities subscription agreement between the Company and the Investor executed on or around 8 June 2018 and as provided to ASIC on 15 June 2018.

Investor means MEF I, LP of 40 Wall Street, Floor 58, New York, United States of America.

Legislative Instrument 2016/82 means ASIC Corporations (Sale Offers: Securities Issued on Conversion of Convertible Note) Instrument 2016/82.

Shares means ordinary fully paid shares in the Company.

Dated this 20th day of June 2018

Signed by Peter Deakin

as a delegate for the Australian Securities and Investments Commission